Contract drugmaker Recipharm is promising to spend $45 million (€40 million) over the next three years to improve drug traceability in an effort to comply with new regulations and combat the rise of fake medicines.
The government of Japan is changing the lucrative brand-name healthcare market as its population ages and requires more drugs with a push to make at least 80% of the government's drug spending be for generics.
Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh.
Onyx Scientific is set to increase the size of its U.K.-based site by more than 30% as it enjoys the spoils of a lucrative 2015.
Amgen said that the approval for Repatha (evolocumab) in Japan filed by Amgen Astellas Biopharma K.K., a joint venture with Tokyo-based Astellas Pharma, could be launched within months pending reimbursement details.
Beijing-based Sinovac Biotech has secured its good manufacturing certificate from the China FDA, placing it on track to sell the Enterovirus 71 (EV71) vaccine to prevent hand, foot and mouth disease.
Mumbai-based drugmaker Wockhardt is once again in the crosshairs of the U.S. Food and Drug Administration (FDA) after the American regulator found the pharma giant was hiding the results from failed tests on drugs and deleting the resulting data from computer systems at a plant in western India, according to a report by Reuters.
Drugmakers in South Korea are moving in to take market share from GlaxoSmithKline, which saw its prostatic hyperplasia and hair loss medication treatment Avodart (dutasteride) go completely off-patent.
Outside of the main markets in China, Japan and India in Asia are closely followed plays in Indonesia, Thailand, Malaysia and Vietnam with the last two among 11 nations that signed the Trans-Pacific Partnership trade pact.
Tokyo-based general contractor Chiyoda, which recently won a $42 million contract to build a production plant for injectable cancer drugs, plans to compete for more such business as its energy-related projects start to slow due to the low price of oil.